Sionna reports positive Phase 1 data for NBD1 stabilizers SION-719 and SION-451; advances both to next trials

Sionna Therapeutics, Inc.

Both SION-719 and SION-451 were generally well tolerated with no serious adverse events or discontinuations.
Both compounds met exposure thresholds from preclinical CFHBE model, indicating potential for clinically meaningful benefit.
SION-719 to advance to Phase 2a proof-of-concept add-on trial in CF patients; initiation H2 2025, topline mid-2026.
SION-451 to advance to Phase 1 dual combination trial with SION-2222 and SION-109; initiation H2 2025, topline mid-2026.
FDA cleared IND for SION-719; first subject dosed in midazolam drug-drug interaction study.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.